Attovia Therapeutics, Inc.(ATTO)

Biotechnology · San Carlos, CA

$17.80-0.20 (-1.09%)

Delayed quote: Oct 6, 2026, 2:30 PM EDT

Attovia Therapeutics (ATTO) EBITDA Yield: History & Chart | TGMCharts

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T18:30:30.325Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:30:30.325Z.

Quote observation: 2026-10-06T18:30:09.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 765,895,273
Total debt · period ending 2026-06-30: 4,325,999
Cash · period ending 2026-06-30: 32,829,000

FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ATTO EBITDA Yield Metrics

EBITDA YIELD

N/A

ATTO Competitors' EBITDA Yield

ATTO

Attovia Therapeutics, Inc.

Current

Market Cap

$765.90M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLAB

Mesa Laboratories, Inc.

vs ATTO

Market Cap

$759.58M

EBITDA Yield

5.47%

TTM Avg

6.26%

3Y Avg

5.92%

5Y Avg

4.44%

LXRX

Lexicon Pharmaceuticals, Inc.

vs ATTO

Market Cap

$775.12M

EBITDA Yield

N/A

TTM Avg

7.18%

3Y Avg

23.84%

5Y Avg

23.84%

VREX

Varex Imaging Corporation

vs ATTO

Market Cap

$778.22M

EBITDA Yield

9.45%

TTM Avg

3.95%

3Y Avg

8.15%

5Y Avg

8.61%

SANA

Sana Biotechnology, Inc.

vs ATTO

Market Cap

$780.61M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AHCO

AdaptHealth Corp.

vs ATTO

Market Cap

$785.58M

EBITDA Yield

15.08%

TTM Avg

18.56%

3Y Avg

15.22%

5Y Avg

13.39%

APMD

Apnimed, Inc.

vs ATTO

Market Cap

$747.48M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DSGN

Design Therapeutics, Inc.

vs ATTO

Market Cap

$748.55M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GERN

Geron Corporation

vs ATTO

Market Cap

$782.66M

EBITDA Yield

N/A

TTM Avg

0.13%

3Y Avg

0.13%

5Y Avg

0.13%

GYRE

Gyre Therapeutics, Inc.

vs ATTO

Market Cap

$794.92M

EBITDA Yield

N/A

TTM Avg

1.34%

3Y Avg

2.25%

5Y Avg

2.25%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Attovia Therapeutics, Inc. (ATTO)	$765.90M	N/A	N/A	N/A	N/A
Mesa Laboratories, Inc. (MLAB)vs ›	$759.58M	5.47%	6.26%	5.92%	4.44%
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$775.12M	N/A	7.18%	23.84%	23.84%
Varex Imaging Corporation (VREX)vs ›	$778.22M	9.45%	3.95%	8.15%	8.61%
Sana Biotechnology, Inc. (SANA)vs ›	$780.61M	N/A	N/A	N/A	N/A
AdaptHealth Corp. (AHCO)vs ›	$785.58M	15.08%	18.56%	15.22%	13.39%
Apnimed, Inc. (APMD)vs ›	$747.48M	N/A	N/A	N/A	N/A
Design Therapeutics, Inc. (DSGN)vs ›	$748.55M	N/A	N/A	N/A	N/A
Geron Corporation (GERN)vs ›	$782.66M	N/A	0.13%	0.13%	0.13%
Gyre Therapeutics, Inc. (GYRE)vs ›	$794.92M	N/A	1.34%	2.25%	2.25%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ATTO EBITDA Yield Metrics

ATTO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics